Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485645 | 0.81 | CA12 (0.32) | MAPT | |
| SCHEMBL2921860 | 0.75 | LMNA (0.39) | MEN1KMT2ALMNAHTT | |
| SCHEMBL10671732 | 0.75 | LMNA (0.39) | MEN1KMT2ALMNAHTT | |
| SCHEMBL10673924 | 0.75 | LMNA (0.39) | MEN1KMT2ALMNAHTT | |
| Diethanolamine SCHEMBL5569921 | 0.71 | — | — | |
| SCHEMBL7960405 | 0.69 | MAPT (0.38) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL10828032 | 0.68 | CA12 (0.45) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL11160258 | 0.67 | — | — | |
| SCHEMBL995987 | 0.66 | TSHR (0.37) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL571432 | 0.66 | TSHR (0.35) | MEN1KMT2AMAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199560-A1 | Bisaryl compound and medicament for cancer treatment comprising the same | KYOWA HAKKO KOGYO CO., LTD. | 2003-10-23 | — | — | US | disclosed |
| US-6608061-B2 | Antiproliferative agents | KYOMA HAKKO KOGYO CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030018070-A1 | BISARYL COMPOUND AND MEDICAMENT FOR CANCER TREATMENT COMPRISING THE SAME | FUJIFILM CORPORATION (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-0990439-A1 | BISARYL COMPOUNDS AND CANCER REMEDIES CONTAINING THE SAME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018070-A1 | BISARYL COMPOUND AND MEDICAMENT FOR CANCER TREATMENT COMPRISING THE SAME | AR, NR5A1, SRD5A1 | MEN1 1157/4885KMT2A 1009/4885MAPT 4649/4885 |
| US-20030199560-A1 | Bisaryl compound and medicament for cancer treatment comprising the same | AR, NR5A1, SRD5A1 | MEN1 1157/4885KMT2A 1009/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.